NCT03624543View on ClinicalTrials.gov

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 14, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

CFI-400945

32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily

Trial Locations (6)

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N6A 5W9

London Regional Cancer Program, London

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M4N 3M5

Odette Cancer Centre, Toronto

M5G 2M9

University Health Network, Toronto

S4T 7T1

Allan Blair Cancer Centre, Regina

All Listed Sponsors
collaborator

Stand Up To Cancer Canada-Canadian Cancer Society Breast Cancer Dream Team

UNKNOWN

lead

Canadian Cancer Trials Group

NETWORK

NCT03624543 - CFI-400945 in Patients With Advanced/Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter